Solasia Pharma K.K.
Latest Information on Our Development Candidate SP-05 Phase Ib/II Clinical Trial (Disclosure of Licensor Isofol Information)
Isofol Medical AB announced the latest information on the Phase Ib/II clinical trial of SP-05. Evaluation at a dose of 500 mg/m² showed a favorable safety profile, numerous cases of tumor shrinkage, and an increased number of patients eligible for surgical intervention. The Phase II will expand sites and participating countries. A concurrent Phase II clinical trial in Japan is also planned. There is no direct impact on fiscal year 2026 results.
Key Figures
- Number of patients assessed as candidates for surgical intervention: 5 cases (out of 10 total treated patients)
- Approximate 50% reduction in maximum tumor diameter (assessed based on RECIST 1.1)
- Continued evaluation at a dose of 500 mg/m²
AI要約
Key Points of the News
This communicates Isofol's latest disclosure regarding the Phase Ib/II clinical trial of SP-05. Evaluation at 500 mg/m² continues in Phase Ib with no safety concerns observed; many patients demonstrated disease control and tumor shrinkage. Five patients were assessed as candidates for surgical intervention and discontinued from the trial. The recommended dose for Phase II has been determined, and an expansion of facilities and participating countries has been decided. A Phase II trial in Japan is planned to run in parallel. There is no direct impact on fiscal year 2026 financial results.
Outlook and Impact
Expanding the facilities and participating countries for Phase II will increase trial opportunities and geographic reach, potentially leading to long-term indication expansion and business opportunities. However, the information in this press release relates to clinical trial progress and does not directly translate into short-term financial metrics. The parallel trial plan in Japan suggests potential future clinical development progress and expansion of business opportunities.
Solasia Pharma K.K.
Company overview · Stock price · Financial data · All IR
